urothelial cancer

IDEAYA reports Phase 1 expansion data for IDE397
MSN/Seeking Alpha
Sun, 10/27/24 - 07:45 pm
Ideaya
clinical trials
IDE397
MTAP
urothelial cancer
lung cancer
Padcev, Keytruda, and Balversa leave little room for Opdivo in urothelial carcinoma
Clinical Trials Arena
Thu, 03/21/24 - 06:41 pm
bladder cancer
urothelial cancer
Merck
Pfizer
Bristol Myers Squibb
Padcev
Keytruda
Balversa
Opdivo
UroGen submits new drug application to FDA for UGN-102
Pharmaceutical Business Review
Thu, 01/25/24 - 11:31 am
Urogen
FDA
UGN-102
urothelial cancer
Johnson & Johnson wins full FDA approval for bladder cancer therapy Balversa
Seeking Alpha
Sun, 01/21/24 - 05:11 pm
JNJ
bladder cancer
Balversa
erdafitinib
urothelial cancer
BMS chases Merck/Seagen with first-line bladder cancer filing
Pharmaphorum
Tue, 12/5/23 - 11:53 pm
Bristol Myers Squibb
Opdivo
bladder cancer
urothelial cancer
Merck
Seagen
Merck, Seagen and Astellas Get Late-Stage Win in Bladder Cancer with Combo
BioSpace
Fri, 09/22/23 - 11:53 am
Merck
Seagen
Astellas
urothelial cancer
clinical trials
bladder cancer
Padcev
Keytruda
ASCO-GU – Bicycle tries to put distance between itself and Seagen
EP Vantage
Thu, 02/16/23 - 10:15 am
ASCO-GU
Bicycle Therapeutics
Seagen
Padcev
urothelial cancer
BT8009
Adaptimmune Reports Positive Data in its SURPASS Trial; Outlines Plans for Advanced Clinical Development in Multiple MAGE-A4 Positive Solid Tumors
Yahoo Finance
Fri, 09/9/22 - 11:03 am
ESMO
Adaptimmune
clinical trials
ADP-A2M4CD8
ovarian cancer
head and neck cancer
urothelial cancer
ESMO: Seagen's Padcev pulls its weight in combo with Merck's Keytruda
Fierce Pharma
Thu, 09/8/22 - 04:40 pm
Merck
Keytruda
Astellas
Seagen
Padcev
ESMO
urothelial cancer
Bicycle Therapeutics shares fall 23% after the company shares interim Phase 1 data
Marketwatch
Mon, 04/11/22 - 10:39 am
AACR
Bicycle Therapeutics
clinical trials
urothelial cancer
BT8009
The markets refuse to forgive Infinity
EP Vantage
Wed, 07/28/21 - 10:09 am
Infinity Pharmaceuticals
eganelisib
urothelial cancer
#ASCO21: Ahead of August PDUFA date, Astellas and Seagen sweeten Padcev pitch with new data
Endpoints
Thu, 05/20/21 - 12:16 pm
ASCO 2021
Astellas
Seagen
Padcev
FDA
urothelial cancer
Seagen, Astellas report positive results from PADCEV phase 2 trial in advanced urothelial cancer
Pharmaceutical Business Review
Tue, 10/13/20 - 11:08 am
Seagen
Astellas
clinical trials
EV-201
urothelial cancer
Mirati's Sitravatinib Shows Promising Phase II Results in Urothelial Cancer Patients
BioSpace
Mon, 09/21/20 - 11:40 pm
Mirati Therapeutics
sitravantinib
ESMO
urothelial cancer
Esmo 2020 – some backing for Beigene’s unusual combo approach
EP Vantage
Mon, 09/21/20 - 10:26 am
ESMO
BeiGene
urothelial cancer
Mirati's sitravatinib in combination with nivolumab shows 37% response rate in urothelial cancer
Seeking Alpha
Fri, 09/18/20 - 10:45 am
ESMO
Mirati Therapeutics
clinical trials
sitravantinib
Opdivo
urothelial cancer
UroGen Gets FDA Nod for Low-Grade Upper Tract Urothelial Cancer Drug
Xconomy
Wed, 04/15/20 - 11:27 pm
Urogen
urothelial cancer
FDA
Jelmyto
Seattle Genetics Issue Update on Padcev Label Expansion Study
Yahoo/Zacks.com
Sat, 04/4/20 - 11:21 pm
Seattle Genetics
Padcev
Merck
Keytruda
urothelial cancer
Roche's Tecentriq fails trial in form of urothelial cancer
Reuters
Fri, 01/24/20 - 10:08 am
Roche
Genentech
clinical trials
Tecentriq
urothelial cancer
bladder cancer
Here's Why Seattle Genetics Climbed 17.6% in September
Motley Fool
Mon, 10/7/19 - 11:25 pm
Seattle Genetics
ESMO
clinical trials
tucatinib
colorectal cancer
enfortumab vedotin
urothelial cancer

Pages